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ABSTRACT
BACKGROUND: Identification of reliable predictors of axillary lymph node metastases (ALNM) may be
useful in selecting appropriate management for patients with T1-size breast cancer. This study was
undertaken to determine the association between ALNM and several variables, including age, tumor size,
grade, estrogen receptor status, progesterone receptor status, p53 and c-erbB2 protein expression, and
Ki-67 proliferative index. 
METHODS: In a retrospective study, 74 patients with pT1b and pT1c ductal invasive breast carcinoma
and with known nodal status were analyzed. The size of the infiltrating tumor was microscopically eval-
uated. The histological grading was performed using the modified criteria of Bloom and Richardson, as
described by Elston and Ellis. The immunophenotype of the tumor was determined as: the expression of
estrogen (ER) and progesterone (PR) receptors, p53, c-erbB2 and Ki-67. The patients were grouped by
age as follows: <50, 50-70, and >70 years old.
RESULTS: Twenty six patients (35%) were node positive. Tumor size was related directly to nodal posi-
tivity. Nodal positivity was significantly related to negative PR status, p53 protein overexpression and
high Ki-67 index (p<0.05). No significant association was found between nodal positivity and patient
age, tumor grade, ER status, and c-erbB2 expression.
CONCLUSION: These data suggest that PR status, Ki-67 proliferation index, and p53 protein expression
might provide additional information to the lymph node status in T1 ductal breast carcinomas.
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INTRODUCTION 
T
he number of tumor-related features available to predict the prognosis of patients with
breast cancer has grown impressively in recent years. Lymph-node status, tumor size
and histologic grade are now supplemented with measurements of steroid hormone recep-
tors, proliferation index, ploidy, tumor suppressor genes, growth factors, oncogenes, and
oncogenes products (1-4). One of the best-established genes for tumorigenesis that is
found to be amplified in patients with breast cancer is c-erbB2. The function of this gene is
to act as a growth factor receptor. It is a well known prognostic and predictive factor in
breast cancer (4-6). The p53 tumor suppressor gene, located on the short (p) arm of chro-
mosome 17, is another established breast cancer progression gene that regulates the cell
cycle and DNA repair. The mutation of p53 is associated with genetic instability (4,7,8).
Apart from progression and suppressor genes, some of which have clearly been shown to
possess prognostic value, a number of other molecules, are also biologically important in
initiation and progression of breast cancer. Among them are an estrogen regulated protein
Factor VIII, and Ki-67.
The presence of lymph node metastases in breast carcinoma is directly proportional to
tumor size. The axillary lymph nodes are affected in less than 10% of all cases of pT1a and
non-palpable pT1b early breast carcinoma (9). Mammographic screening, which allowed
the early detection of breast carcinomas with a low risk of lymph node metastases, has pro-
moted a series of studies that debated the usefulness of axillary node dissection.
However, the frequency of lymph node metastases associated with small tumors is too vari-
able to rule out axillary dissection altogether (10-12). There are other clinical and patholog-
ical factors that might influence the nodal status in pT1 breast cancer (10,13). 
For many years, axillary dissection has been a routine method for determining the status of
axillary lymph nodes. The recent introduction of the sentinel lymph node procedure has
already reduced the number of unnecessary lymphadenectomies and the number of axillary
dissection associated complications. However, some patients will require chemotherapy
even thought the sentinel lymph node is negative (14,15).
The evaluation of the specific tumor phenotype and the clinical features of each single
patient need to be considered for the provision of individualized treatment. To provide this
information, we evaluated the correlation between tumor size and lymph node status in a
series of 74 pT1ductal breast carcinomas. In addition, we evaluated which clinicopatholog-
ical factors correlating with lymph node metastases in patients with T1 ductal invasive
breast cancer.MATERIAL AND METHODS
We studied 74 patients with pT1 ductal invasive breast carcinoma who underwent total axil-
lary dissection between 1998 and 2001, in the Institute of Oncology, Sremska Kamenica.
None of the patients was submitted to sentinel node procedure. 
Palpable tumors were cut along their major diameter and measured. Because all the lesions
examined  were <2 cm, it was possible to confirmed microscopically the gross evaluation
of tumor size. Non-palpable lesions were identified by a hook-wire. In non-palpable lesions,
tumor size was microscopically measured and the largest diameter of the invasive compo-
nent was reported. When the invasive tumor was associated with in situ carcinoma, only
the invasive carcinoma was considered for tumor staging. Tumors were categorized using
the TNM system (16). Invasive carcinomas were classified as pT1b (6-10 mm) and pT1c
(11-20 mm).   
Surgical specimens were 10% buffered formalin fixed and paraffin wax embedded; 4 ￿m
sections were cut and stained with hematoxylin and eosin (H&E). Two to five sections for
each block were examined after H&E staining. The histological grading was performed
using the modified criteria of Bloom and Richardson, as described by Elston and Ellis (17).
The streptavidin-biotin peroxidase complex method was used for immunohistochemistry.
Briefly, 4 ￿m sections were cut from paraffin wax blocks, dewaxed, and hydrated through
graded alcohols to water. Estrogen (ER) and progesterone (PR) receptor (Dako, Glostrup,
Denmark), p53 (Dako, Glostrup, Denmark), and c-erbB2 (Dako, Glostrup, Denmark)
immunostainings were performed, preceded by antigen retrieval with incubation in 10 mM
citrate buffer for 5 minutes at 100 W and 15 minutes at 800 W (domestic microwave), in
thermo resistant container. Distilled water and buffer were added every 5 minutes to the
container to prevent drying during the incubation process. Immunostaining for Ki-67 (Dako,
Glostrup, Denmark) was carried out with no previous antigen retrieval step. Following
endogenous peroxide and protein blocking step, the slides were incubated with primary
antibodies. After brief washes, incubation in a cocktail of biotinylated rabbit anti-mouse
IgG/IgM for 30 minutes was performed. The sections were then washed and incubated with
streptavidin-biotinylated horseradish peroxidase complex for 30 minutes reacted with 3-
amino-9-ethylcarbazole (AEC, DAKO) and hydrogen peroxide to visualize the end product.
Hematoxylene was used as counter stain.
Nuclear staining for hormone receptors, Ki-67 and p53, and membranous staining for c-
erbB2 were evaluated. Cut off values for positivity were established as follows: ER, PR, p53
and Ki-67: >10% marked and very strong nuclear staining; c-erbB2: >10% weak to mod-
erate and strong complete membrane staining (18).
Negative controls were carried out by omission of the primary antibody. As positive con-
trols, sections from previously studied cases of breast cancer know to express ER, PR,
p53, c-erbB2 and Ki-67 were used.
Statistical differences between lymph node status and tumor size, histological grade, ER
and PR content, p53 expression, c-erbB2 expression and Ki-67 expression were calculat-
ed using the c2 test and Students t test. A value of p<0.05 was considered significant.
RESULTS
Of 74 patients with T1 ductal invasive breast carcinoma, 24 (32.4%) had pT1b, and 50
(67.6%) had pT1c tumors (Table 1). There were not cases of pTa tumors in our study.
The mean age of all patients was 58–12.1 years. Axillary metastatic lymph nodes were
found in 26 of 74 patients (35%). The number of lymph nodes recovered from all speci-
mens ranged from 10 to 24.
Tumor size was related directly to nodal positivity. Cases of IC pT1b were less frequently
node positive, than pT1c tumors (21% v 42%; p<0.1). In lymph node positive patients the
mean size of tumors was significantly larger than in group of lymph node negative patients
(1.59–0.42 cm v 1.36–0.46 cm; p<0.05).
Of 74 patients, 57 (77%) had ER positive tumors, and 55 (74%) had PR positive tumors
(Figure 1). In progesterone receptor positive tumors, the percentage of node positivity was
significantly lower than in progesterone negative tumors (27% v 58%; p<0.01).
In our group of patients, there were 14 (19%) patients with positive tumors p53 protein
expression (Figure 2).
In tumors with positive p53 protein expression, the percentage of node positivity was sig-
nificantly higher than in p53 protein negative tumors (64% v 28%; p<0.05).
Ki-67 proliferative index was significantly related to nodal positivity. In fact, 43% (23 of 53)
of cases with high proliferative index were node positive compared with 14% (3 of 21) of
tumors with low Ki-67 proliferative index. In our group of patients, c-erbB2  overexpression
was determinated in 10 (13.5%) cases (Figure 3).
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Table 1. Relation between node positivity and different tumor clinicopathological  parame-
ters in the 74 patients
Figure 1. Intense nuclear localization of estrogen receptors was detected in tumor cells, 
B-SA, x100No significant relation was found between nodal status and patient age at diagnosis, histo-
logical grade, ER status, and c-erbB2 expression.
DISCUSSION
Axillary lymph node status and tumor size have long been considered to be the most sig-
nificant prognostic factors for breast cancer patients (1-4).
This study reports an overall rate of axillary lymph node metastases of 35% among 74
women with ductal invasive breast carcinomas measured †2 cm. In our study, we con-
firmed that tumor size remains an important predictor of axillary node metastases in breast
carcinomas. However, we showed that other factors as p53 overexpression, PR status and
Ki-67 proliferative index correlate with ALNM. 
Contrasting data have been published previously on the incidence of axillary lymph node
metastases according to tumor size (10-13,19). Overall, the rate of ALNM in patients with
pT1 breast cancers has been reported to be from 18 to 38.5%. Axillary metastasis rates for
pT1a (†0.5 cm) tumors have varied even more widely, from 0% to 28%. This variability
might have several causes, such as the need to examine a sufficient number of lymph
nodes to obtain reliable results, and the poor reproducibility of the measurement of small
invasive cancers. The definition of tumor size in the literature varies significantly, possibly
affecting the incidence of positive lymph nodes too. In our work tumor diameter was deter-
minated microscopically (10). This allowed us to limit our measurement to the invasive
component of each tumor, and to exclude the associated in situ component. Seidman and
co-workers demonstrated that this kind of tumor size measurement is a better predictor of
lymph node status than the total tumor size (20). Abner at al. demonstrated that the rate of
axillary lymph node metastases associated with macroscopic tumor size did not differ sig-
nificantly from that associated with microscopic tumor size (21). The relatively large tumor
size of our sample without pT1a cases may partly explain the high rate of nodal involvement
in this series. 
Among patients affected with small breast cancer, younger patients have a higher incidence
of axillary nodal metastases than older patients. Mustafa et al. demonstrated that young age
is a strong predictor of nodal metastases in univariate and multivariate analyses of 2185
patients with invasive breast carcinomas measuring †1 cm (22). Additionally, histological
grade and nuclear grade are also significantly associated with ALNM. The discrepancy
between our findings and those from other studies may be caused by the relatively small
number of cases of our sample, and differences in the grading methods used to evaluate
the histological malignancy grade. Beside, the malignancy grade of the invasive breast car-
cinoma is a powerful prognostic factor in tumors larger than 10-15 mm.
The presence of steroid hormone receptors  (ER and PR) represents a relatively weak prog-
nostic factor for patients with breast cancer, but these receptors are the strongest predic-
tive factors for response to hormonal therapy. Most of the tumors are obviously receptor-
positive (1-3). Our series demonstrated that PR-negative status was significantly associat-
ed with axillary node metastases. Wenger et al. demonstrated that steroid receptor status,
S-phase fraction and DNA ploidy were associated with axillary nodal positivity (23). Ravdin
et al. found tumor size, patient age and progesterone receptor status to be independent pre-
dictors of axillary nodal status in breast cancer patients with tumors of †5 cm (24).
In our study, we found p53 protein expression and high Ki-67 score are associated with
ALNM. Gasparini et al. reported that high Ki-67 scores are associated with poor histologic
differentiation and with lymph node metastasis (25).
In our study, 10 (13.5%) patients with pT1 tumors had c-erbB2 protein overexpression.
Generally, the HER2/neu gene has been found to be amplified and/or overexpressed in
approximately 20 to 30% of invasive breast cancers, most commonly in invasive ductal car-
cinomas (5). C-erbB2 expression showed no significant differences between the node neg-
ative and node positive patients in our groups. Arisio et al. found no significant correlation
between nodal positivity and ER, PR,53 and c-erbB2 status (10). There are many studies
that have shown that HER2 overexpression is associated with other adverse prognostic fac-
tors such as positive lymph nodes, larger tumor size, high proliferative index, high histologic
grade, p53 mutation, intratumoural necrosis, and lack of expression of estrogen and prog-
esterone receptors (26,27). 
CONCLUSION
Our study has demonstrated association of large tumor size, lack of expression of proges-
terone receptors, p53 protein overexpression, and Ki-67 high proliferative index with axillary
lymph node involvement in pT1 ductal invasive breast cancer. However, it is difficult to
characterize a subgroup that has an acceptably low risk of nodal involvement, since the
impact of each factor on the reduction of lymph node positivity is relatively small. The indi-
cations provided by the pathological parameters of the tumor, together with the clinical data,
might provide additional information to the histology of lymph nodes, and might be useful
for individualized treatments.
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Figure 2. Intense nuclear localization of p53 protein was detected in tumor cells, suggest-
ing accumulation of abnormal mutant p53 protein, B-SA, x200
Figure 3. A strong membrane staining for c-erbB2 (HER2) was observed in tumor cells, B-
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